WDFY3 and breast neoplasm: Recently, Deva Magendhra Rao et al. [52], using RNA sequencing to determine the expression profile of lncRNA in breast cancer, identified WDFY3-AS2 as down-regulated in early-stage breast tumors, which was validated in 52 tumor samples.